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The therapeutic benefit of depleting B cells in rheumatoid arthritis (RA) has refocused attention on B cells with increasing awareness
on their role in autoimmunity and their function beyond autoantibody production. The rapid increase in our comprehension of
B-cell pathobiology is progressively opening novel perspectives in the area of B cell-targeted therapies with the expectation to define
more specific approaches able to preserve the homeostasis of the humoral response while disrupting the pathogenic components. In
parallel, B-cell activity in RA is starting to be explored in its clinical value, in search of novel biomarkers embedded in the pathogenic
process that could help classifying the disease and predicting its heterogeneous outcome beyond inflammation dynamics. In this
review, we summarize current knowledge on the multiple roles that B cells play in several aspects of RA. We also analyze their
distribution and potential function in different anatomic compartments with specific reference to themain sites inwhich the disease
may be sustained and exert its detrimental effects: the systemic circulation, synovium, bone marrow, and draining lymph nodes.
We also highlight novel data encouraging further research in the field of biomarkers related to B cells and their regulatory factors.
1. Introduction
The history of the pathogenic involvement of B cells in
rheumatoid arthritis (RA) has spanned glories and hurdles.
The discovery of rheumatoid factors (RFs) byWaaler in 1937–
1939 and Rose in 1948 fueled the attractive hypothesis that
RA pathogenesis mostly relied on antigen-antibody reactions
in the joints, activating the cascade of complement and
promoting chemotactic migration of polymorphs, the final
effectors of articular damage [1]. The lack of specificity of
RFs for RA rapidly shifted the attention to alternative players,
such as macrophages and T cells, which have dominated the
scene for decades leading to the development of effective
targeted therapies [2]. After years of impasse, the therapeutic
benefit and safety of depleting B cells in mice and humans
[3, 4] have refocused attention on B cells and their role in
autoimmunity beyond autoantibody production [5, 6]. As
knowledge on B-cell biopathology increases, developments
in the area of B cell-targeted therapies are moving fast [7].
Equally exciting, the cellular and molecular signatures of
B-cell activity in patients with RA are starting to be explored
in their clinical value, in search of novel biomarkers beyond
conventional autoantibodies that could help better classifying
the disease and predicting its heterogeneous outcome. In this
review, we summarize current knowledge on the multiple
and unexpected roles that B cells play in several aspects
of RA immunopathology, analyze their redistribution in
different anatomic compartments, and highlight novel data
encouraging further research in the field of B-cell biomarkers.
2. Primary Defects in the Generation
of the B-Cell Repertoire and Peripheral
Tolerance Checkpoints
In healthy individuals, most autoreactive B cells are removed
at 2 discrete steps [8, 9]. A central B-cell tolerance check-
point in the bone marrow between early immature and
immature B cells removes the vast majority of B cell clones
expressing polyreactive antibodies and antinuclear anti-
bodies. A peripheral B-cell tolerance checkpoint further
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counter selects autoreactive new emigrant/transitional B cells
before they enter the long-lived mature naive B cell pool.
Central B-cell tolerance is mostly controlled by intrinsic B-
cell factors regulating B-cell receptor (BCR) and Toll-like
receptor (TLR) signaling as well as the expression levels of
the enzyme activation-induced cytidine deaminase (AID),
which is required for class-switch recombination and somatic
hypermutation of the immunoglobulin (Ig) genes [10]. In
contrast, peripheral B-cell tolerance seems to involve extrin-
sic B-cell factors such as regulatory T cells (Treg) and serum
B-cell activating factor (BAFF) concentrations [10].
Both central and peripheral B-cell tolerance checkpoints
are defective in RA, resulting in the accumulation of a large
number of autoreactive B cells in the mature naive B cell
compartment [9]. In untreated patients with active RA, the
frequency of polyreactive new emigrant/transitional B cells
in the peripheral blood was found to increase for 3.4-fold
compared to control subjects, highlighting the inability to
remove polyreactive B cells in the bone marrow [9]. Many
susceptibility genes associated with RA, such as tyrosine
phosphatase nonreceptor type 22 (PTPN22), have been
shown to affect BCR signaling pathways. Accordingly, similar
central B-cell tolerance defects are observed in healthy single
PTPN22 risk allele carriers and in active RA [10]. Increased
frequencies of polyreactive new emigrant/transitional B cells
indicative of a defective central B-cell tolerance checkpoint
are also observed in association with genetic defects of
involving TLR signaling and AID activity [10], but the
possible association of these susceptibility genes with RA
development is currently unknown. Importantly, impaired
central B-cell tolerance in patients with RA is not resolved
by effective treatment regimens that reduce inflammation,
confirming the relevance of intrinsic genetic predispositions
over and above the imbalance of proinflammatory cytokines
at this early checkpoint [11].
The increased frequency of mature naive B cells express-
ing both polyreactive and HEp-2-reactive antibodies in
patients with RA indicates further defects in peripheral B-cell
tolerance checkpoints [9]. Treg function is impaired in RA
with respect to suppression of CD4 T cells [12]. In contrast, it
has been recently shown that defective regulation of autore-
active B cells in patients with RA is due not only to intrinsic
defects in Tregs but also as a result of B-cell resistance to
suppression due to resistance to Fas-mediated apoptosis [13].
Increased levels of BAFF, as detected systemically [14, 15]
and, more importantly, within the joint compartment of
patients with RA [16, 17], may further foster the survival
and maturation of autoreactive B cells. The potential sources
of BAFF in autoimmune diseases are incredibly diverse and
include haematopoietic and nonhaematopoietic cell lineages
[18]. Relevantly, BAFF expression is increased in the presence
of several types of cytokines and chemokines as well as
by the activation of TLRs [18]. The production of BAFF
by nonhaematopoietic cells might provide local niches to
modulate the survival and function of B cells. Accordingly,
BAFF expression by synovial fibroblasts in response to TLR
signaling has been shown to promote Ig class switching
via AID induction [19, 20]. Furthermore, TLR signals per
se are costimulatory and critically regulate T-independent
autoreactive B cell activation and isotype-switch of Ig genes
outside germinal centres (GCs) [21].
3. Different Roles of B Cells in
RA Pathobiology
Thepathogenic roles of circulating and tissue-localizedB cells
in RA can occur through several mechanisms that include
autoantibody production, T-cell activation, and cytokine
synthesis. Recent seminal works have also shed new light
onto B-cell regulatory functions in the context of immune-
mediated inflammation and revealed an unexpected role of B
cells in bone homeostasis (Figure 1).
3.1. Autoantibody Production. A large number of different
antigens are recognized by the antibody repertoire in RA, and
the list of RA-associated autoantibodies continues to expand
(Table 1).The twomost widely studied autoantibody systems,
whose importance is also underscored by their inclusion in
the clinical management of patients with RA, are RFs and
anticitrullinated protein antibodies (ACPA).
Understanding how these autoantibodies are generated
has catalyzed considerable efforts in search of the mecha-
nisms that initiate and maintain autoimmunity in RA.
An intriguing line of research suggests that autoreactive
responses against self-IgG (generating RFs, which are pre-
dominantly nonswitched IgM) may occur outside GCs at
least initially in a T-independent fashion [22]. Extrafollicular
responses are critically regulated by TLRs and involve self-
antigens containing a TLR-ligand that is recognized by a B
cell-intrinsic TLR, as is the case of self-IgG [21]. Somatic
hypermutation and isotype switch of Ig genes, which classi-
cally characterize T cell-dependent GC responses, can also
occur extrafollicularly upon TLR signaling, and some RF
clones fromRApatients are indeed somaticallymutated com-
pared to healthy subjects [23]. Importantly, although T cells
are not required for the initiation of extrafollicular responses,
they substantially amplify and sustain chronic autoantibody
production via CD40L and interleukin (IL)-21 signaling [21].
In contrast, immunity to citrullinated antigens is thought to
require autoreactive T cells and to develop within classical
GC reactions. ACPA are indeed strongly associatedwithHLA
DR alleles [24] and are switched IgG with strong bias toward
amino acid replacement mutations [25]. It is worth noting
that such postulated disparity in the involvement of TLRs and
T cells for the generation of RF and ACPA responses might
in part explain the differences in treatment-related changes
observed between the two autoantibody systems [26, 27].
3.2. Antigen Presentation, T-Cell Activation, and B-T Cell
Cooperation. B cells can act as efficient antigen presenting
cells (APCs) to stimulate T cells and allow optimal devel-
opment of memory in the CD4+ T-cell population. Com-
pared with nonspecific uptake associated with professional
APCs, selective uptake of antigen by antigen-specific B cells
is markedly superior [28]. Furthermore, RF+ B cells, in
particular, are believed to play an important role in antigen
presentation [29]. They can take up antigen-Ig immune
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Figure 1: The multiple roles of B cells in rheumatoid arthritis. Immune responses potentially orchestrated by B cells in rheumatoid arthritis.
B-T cell interactions result in the activation and differentiation of plasma cells, responsible for the production of autoantibodies (A). In
turn, activated B cells provide help to T cells and induce differentiation of effector T cells that produce proinflammatory cytokines (B).
B cells can also impact on other immune and nonimmune cell functions through secretion of cytokines, such as interleukin (IL)-1, IL-6,
tumor necrosis factor (TNF)-𝛼, and IL-17A (C). Proinflammatory cytokines and receptor activator of nuclear factor 𝜅𝐵 ligand (RANKL)
produced by activated B cells, T cells, macrophages, and synovial fibroblasts promote the differentiation and activation of osteoclasts, leading
to bone resorption (D). Further participation of B cells in bone homeostasis is suggested by the recognition that autoantibodies recognizing
citrullinated vimentin are able to promote the differentiation of mononuclear cells to osteoclasts (D). B cells can also be immunoregulatory
through the provision of IL-10 and other mechanisms yet to be elucidated (E).
complexes via their membrane Ig receptors, which have RF
specificity. B cells then process and present peptides from the
antigen and thus induce both T-cell activation and T-cell help
[29].
Evidences that T-cell responses in RA synovitis can be
dependent on B cells come from studies by Takemura and
coworkers [30]. Treatment with a monoclonal anti-CD20
antibody in severe combined immunodeficient (SCID) mice
xenotransplated with RA synovial tissue enriched in B cells
and GCs led to disruption of GCs, loss of follicular dendritic
cell (FDC) networks, and impairment of T cell activation,
with fall in the production of T cell-derived cytokines.
The recent demonstration that B cells reacting toward
citrullinated peptides are enriched in RA joints [25], together
with the well-recognized expression of citrullinated proteins
in the same anatomic location [31], suggests the possibility
that these mechanisms may also be involved in the amplifi-
cation of autoimmune responses in human disease through a
local cross-talk between citrullinated peptide-reacting B cells
functioning asAPC for citrullinated peptide-specific synovial
T cells.
Besides antigen presentation, B cells could stimulate
pathogenic T-cell responses through cytokine secretion.
Table 1: Autoantibodies described in rheumatoid arthritis.
Rheumatoid factors
Anti-collagen type II
Anti-glucose-6-phosphate isomerase (GPI)
Anti-human cartilage glycoprotein 39
Anti-Ra33/heterogeneous nuclear ribonucleoprotein (hnRNP)
A2
Anti-citrullinated fibrinogen
Anti-citrullinated vimentin
Anti-citrullinated alpha-enolase
Anti-immunoglobulin binding protein (BiP)
Anti-carbamylated proteins (anti-CarP)
Anti-peptidyl arginine deiminase (PAD)
Anti-histones
Anti-Porphyromonas gingivalis-derived enolase
Anti-Porphyromonas gingivalis-derived PAD
A candidate cytokine for such function is IL-6. B cells are a
relevant source of IL-6 in the chronic phase of autoimmune
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diseases [32], including RA [33]. Mice deficient in IL-6
have reduced arthritis severity coupled with impaired IL-
17 production by CD4+ T cells [34]. Furthermore, IL-6
inhibition increases the frequency of functionally suppressive
Tregs in both experimental and human arthritis [35]. IL-
6 has indeed been recently identified as a major regulator
of the balance between effector T helper (Th)17 cells and
Tregs. In the presence of transforming growth factor (TGF)-
𝛽, IL-6 induces de novo differentiation of Th17 from naı¨ve
T cells through upregulation of retinoid orphan receptor-𝛾t,
while it inhibits TGF-𝛽-induced Treg differentiation [36]. In
turn, Th17 cells and Th17 cell derived cytokines have been
shown to promote B-cell proliferation, differentiation, class-
switch recombination, and antibody production in vivo [37],
suggesting the existence of a positive feedback loop between
T and B cells potentially involved in the amplification of
the inflammatory response. In keeping with these concepts,
response to treatment studies on humans demonstrate the
effect of B-cell depleting agents on both B lymphocytes and
Th17 responses in vitro [38]. Whether these mechanisms
are part of chronic synovitis pathogenic cascade in vivo still
remains to be proved.
3.3. Cytokine Production. Besides the potential contribution
of B cells to T-cell differentiation and function, there is
now growing evidence indicating that B cells in RA can
directly contribute to the local synthesis of a wide spectrum
of cytokines acting on other pathologically relevant cell types.
Yeo et al. [33] through gene expression analyses of sorted
cell populations have demonstrated a generally proinflam-
matory role of synovial fluid B cells with recognition of
high expression of the subunits required for functional IL-
12 and IL-23 production, as well as of IL-1𝛼 and tumor
necrosis factor (TNF)-𝛼. Of considerable relevance the same
authors have shown that B cells represent a major source of
receptor activator nuclear factor kappa B ligand (RANKL) in
the rheumatoid environment, suggesting their direct involve-
ment in the process of osteoclastogenesis. In keeping with
these concepts, recent reports have also shown that CD19+
B cells from both RA patients and healthy individuals are
capable of producing IL-17A [39], a pleiotropic cytokine
involved in multiple aspects of immune function, inflamma-
tion, and bone damage. There is also evidence that B lineage
cells infiltrating the inflamed synoviummay induce cytokine
synthesis in synovial fibroblasts through the production of IL-
36𝛼 [40], suggesting the capacity of tissue infiltrating B cells
to interact not only with haematopoietic cells but also with
the local stroma through paracrine mechanisms.
3.4. Immune Regulation. Whilst the above paragraphs would
support the role of B cells as humoral effectors, APCs,
and proinflammatory cytokine producers, there is now evi-
dence that specific subsets of B cells can actually func-
tion as regulatory elements, controlling local inflamma-
tory pathology. Recent studies on humans demonstrate
that CD19+CD24hiCD38hi peripheral blood B cells, a phe-
notype overlapping the one characteristic of recent bone
marrow emigrant B cells (transitional B cells), can exert
suppressive activity in vitro. In coculture systems, activated
CD19+CD24hiCD38hi B cells can indeed suppress T-cell
proliferation, inhibit na¨ıve T-cell differentiation intoTh1 and
Th17 cells, and convert CD4+CD25− T cells into Tregs,
partially via the provision of IL-10 [41–43]. Although several
aspects of regulatory B-cell (Breg) pathobiologic involvement
in RA remain to be clarified, there is now evidence that their
suppressive function is partly impaired during active disease.
The functional impairment of RA Bregs in vitro is coupled
with their reduced frequency in the systemic circulation
compared to healthy controls, a phenomenondetectable from
the early phases of the disease [44] and possibly linked to
their active recruitment to the inflamed joint [42].These data
suggest the potential localization of CD19+CD24hiCD38hi
Bregs in the inflamed synovium and their participation to
human synovitis dynamics. Additional studies are required
to confirm these hypotheses to understand their functional
relationship with other infiltrating lymphocytes and with
synovial B-cell responses in situ.
3.5. Bone Homeostasis. Pathologic bone remodeling is a hall-
mark of RA.The skeletal complications of RA consist of focal
erosion of marginal and subchondral bone, juxta-articular
osteoporosis, and generalized bone loss. Although it is well
established that the enhanced activity of osteoclasts results
from the activation of T cells and the secretion of proinflam-
matory cytokines [45], a previously unappreciated role for B
cells in regulating bone homeostasis has recently emerged.
A step forward was made by the recognition that purified
human autoantibodies recognizing citrullinated vimentin are
able to promote the differentiation of mononuclear cells to
osteoclasts in vitro and therefore directly promote bone loss
[46]. Accordingly, ACPA-positive RA patients show more
pronounced trabecular bone resorption at the distal radius
compared to seronegative patients independent of disease
duration, activity, and treatments [47]. Furthermore, high-
resolution peripheral quantitative computed tomography of
the metacarpal bones has revealed significant bone porosity
in healthy individuals with ACPA compared with controls
without immune reactivity to citrullinated proteins [48].
Whether ACPA are directly causative of bone resorption
in human disease remains to be proven. An alternative or
complementary hypothesis could be that immune responses
against citrullinated proteins elicit subclinical levels of
inflammation which in turn negatively affect bone home-
ostasis through conventional mechanisms. Supporting this
view, some proinflammatory cytokines are upregulated in the
serum of individuals later developing RA [49], andACPA can
acquire a proinflammatory Fc glycosylation phenotype before
the onset of clinical disease [50].
Although less explored, B-cell pathology could be linked
to bone remodeling also besides autoantibodies. As already
discussed, B cells in the joints of patientswithRAmaydirectly
participate to RANKL synthesis [33] and indirectly modulate
the RANKL/osteoprotegerin (OPG) system through the pro-
duction of proinflammatory cytokines, such as TNF and IL-
17A [33, 39]. The net effect of B cells on bone homeostasis
in RA remains however highly controversial and possibly
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depends on several factors including the developmental stage,
the activation state, and the microenvironment in which
B cells are embedded. Accordingly, B cells infiltrating the
subchondral bone marrow of eroded joints in patients with
long-standing disease may be rather involved in healing
processes through the production of bone morphogenetic
proteins [51]. In linewith this observation, it has been recently
shown that repair of bone erosions inRApatients treatedwith
TNF-inhibitors, although rare, is based on bone apposition at
the base of erosion and probably involves the bone marrow
[52].
4. B Cells in Different Compartments
The analysis of B cell distribution, function, and alterations
in the systemic circulation, the synovial tissue, and juxta-
articular locations has been the object of several studies on
RA and experimentalmodels of arthritis, aiming at dissecting
disease immune-dynamics as well as site-specific targets for
biomarker and therapeutic development.
4.1. Peripheral Blood. Although assessments in the peripheral
blood may present minor sensitivity if compared to inflamed
target tissues, the circulation clearly represents an important
anatomic district for pathogenic and translational studies,
being representative of the systemic homeostasis and an
easily accessible compartment for serial measurements in
humans. In systemic diseases characterized by prominent
autoantibody production and B-cell disturbances, such as
systemic lupus erythematosus, several studies have indeed
consistently shown differences of certain peripheral B cell
subsets compared to healthy controls [5].
Data are not equally robust in RA, perhaps because
of variability in disease phenotypes or pathobiology across
different phases. Disturbances in the naı¨ve B-cell compart-
ment have been described in small cohorts of very early (<6
weeks of disease duration) and early (<6 months of disease
duration) RA patients, with a slight (1–1.2 fold) increase in
the frequency of IgD+CD27−CD19+ B cells compared to
healthy controls [53, 54]. However, disease duration, therapy,
or both seem to impact the circulating naı¨ve B-cell pool, as no
significant alterations or decreased frequencies are observed
in patients with established disease treated with either syn-
thetic or biological disease modifying antirheumatic drugs
(DMARDs) [53, 55, 56].
In contrast, changes in the memory B-cell compartment
appear more consistent, with most of the studies suggesting
a reduction in the percentage of CD27+ memory B cells,
involving either the IgD+ preswitched population [53–55] or
the IgD− postswitched fraction [56] or both [57]. Memory B
cells express the chemokine receptors CXCR5, CXCR4, and
CCR7 [58] that account for their migration across different
anatomic compartments under homeostatic and inflam-
matory conditions. Serum levels of their ligands CXCL13,
CXCL12, and CCL19 (which may well reflect the degree of
expression of these factors in peripheral tissues) have been
actually shown to be inversely correlated with the frequency
of blood memory CD27+ B in RA [59], suggesting that there
might be amigration or redistribution of pathogenicmemory
B cells into different anatomic compartments, such as the
inflamed synovium. In keeping with this concept, synovial B
cells are enriched in CD27+ memory B cells compared to the
peripheral blood [51, 55, 58].
4.2. Synovial Tissue. Compared with other conventional cell
populations, such as macrophages and T lymphocytes, B
cells infiltrating the inflamed synovium in RA show the
highest degree of qualitative and quantitative heterogene-
ity [60, 61]. A variable but yet considerable proportion
of synovial tissues indeed completely lacks B cells. When
present, B cells are virtually restricted to follicular struc-
tures with wide variation in size and density distribution
(Figure 2). These structures are the preferential environment
in which topographic interactions between B cells and T cells,
macrophages, mesenchymal stromal cells, and dendritic cells
are favoured, which makes them the elective intrasynovial
site for potential intercellular (cell-contact dependent or
paracrine) immunological interactions to take place [62].
In keeping with this concept, progressive enlargement of
intratissue lymphoid structures and local B-cell enrichment
can be associated with acquisition of molecular, cellular,
and structural features constitutive of secondary lymphoid
organs. These features include the constitution of partly
separated B- and T-cell rich areas, local production of
homeostatic lymphoid chemokines (CXCL13, CCL21), and
differentiation of stromal cells typical of lymphoid tissues,
involved in local antigen- and cell delivery in the B- and T-
cell compartments (smooth muscle actin [SMA]+ CCL21+
CD45− fibroblastic reticular cells, CD21+ FDCs, peripheral
node addressin [PNAd]+ high endothelial venules) [63–65].
Despite the acquisition of the above mentioned structural
features is not systematic, with frequent observation of partly
organized aggregates, there is molecular evidence indicating
that the process of B-cell infiltration in RA can lead to
functionally-competent immunological niches characterized
by GC-like activity. Several in situ data appear to support
this concept: (i) the recent demonstration of local expression
of the enzyme AID and its association with local detection
of circular transcripts, transient by-products of the ongoing
process of immunoglobulin class-switch [66]; (ii) the analysis
of B cell aggregatesmicro-dissected from synovial tissue sam-
ples showing somatic diversification of the V-gene repertoire
[67]; (iii) V-region gene analysis of B cells and plasma cells
from the same tissues suggesting that synovial plasma cells
are largely generated from locally activated B cells [68].
The local activation of autoreactive B cells may be
involved in the generation of pathogenic autoantibodies. As
previously mentioned, monoclonal IgG antibodies generated
from joint-derived B cells of RA patients have actually a
strong bias toward citrullinated autoantigen recognition [25],
andAID-expressing follicular units fromRA synoviumxeno-
transplanted into SCID mice are associated with circulating
human IgGACPA inmouse sera [66]. Accordingly, in human
samples, AID expression levels are associated with IgGACPA
titres in ACPA-positive patients, though high AID synovial
expression can be also observed in ACPA-negative patients,
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Figure 2: The gradient of B-cell infiltration and aggregation in rheumatoid synovitis. (a) Representative examples of progressive degrees
of synovial B-cell infiltration in specimens from 4 independent patients with rheumatoid arthritis stained for the B-cell marker CD20 are
shown. Original magnification: 100x. (b) Validity of the B-cell aggregational score is confirmed by parallel immunohistochemical and mRNA
expression analysis for the B-cell marker CD19. ((c), (d)) The progressive enrichment in synovial B aggregates is coupled with progressively
increasing levels of the B-cell chemoattractant CXCL13 (c) and the cytokine lymphotoxin (LT)-𝛽 (d), known to regulate lymphoid tissue
ontogenesis and neogenesis. ((e)–(g)) B-cell aggregation is associated with the progressive increase in markers reflecting immune cell
activation, such as the B-cell activation marker activation-induced cytidine deaminase (AID) (e) and the T cell-derived cytokines interferon
(IFN)-𝛾 (f) and interleukin (IL)-2 (g). The graphs show mean (SD) expression levels stratified according to the B-cell aggregational score.
and, conversely, ACPA positivity may occur in the absence
of significant B-cell infiltration in the synovium (S. Bugatti,
unpublished observations).
As already mentioned, synovial B cells may orchestrate
additional pathogenic processes besides autoantibody pro-
duction, such as MHC class II-dependent T-cell activa-
tion [30]. Accordingly, tissues enriched in B-cell aggregates
display the highest levels of the T cell-derived cytokines
interferon (IFN)-𝛾 and IL-2 (Figure 2).
4.3. Bone Marrow. In humans, the largest part of B-cell
development occurs in the haematopoietic red marrow.
Furthermore, plasma cells establish their survival niche in
the bone marrow. The involvement of the systemic bone
marrow as a primary site for autoreactive B-cell develop-
ment and autoreactive plasma cell survival in RA is thus
unsurprising. Less expected, under chronic inflammatory
conditions including RA, the systemic bone marrow may
acquire morphological features of a secondary lymphoid
organ. In a unique series of 15 bone marrow trephine biopsy
specimens from RA patients, 9 exhibited a follicular pattern
of infiltrating lymphocytes, and GCs were detected in 5 [69].
Isolated reports have also described B-cell clonality occurring
in association with marrow lymphoid follicles [70].
Evidence has accumulated over the years that bone
marrow changes in RA also involve the subchondral bone
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marrow of peripheral joints [71]. This is normally a fat-rich
tissue devoid of significant immunologic activity. In eroded
joints of patients with long-standing RA, the fat is replaced
by an immune-inflammatory infiltrate that organizes into
follicles [51, 72, 73]. Although marrow follicles share most of
the morphological features of synovial lymphoid aggregates
[51, 72], they are enriched in memory B cells and plasma cells
[51]. Functionality at these sites has yet to be demonstrated,
and the actual contribution of subchondral bone marrow
B cells to the immunological disturbances of RA is not
proven. However, since the recognition that bone marrow
involvement in magnetic resonance imaging (bone marrow
edema) occurs very early in course of the disease [74, 75]
and strongly predicts radiographic progression [76], it has
been tempting to speculate that inflammation and lymphoid
infiltration within the subchondral aspect of the joints in RA
patients actively contribute to local bone damage.Though, as
already mentioned, the effects of B cells on bone remodeling
might be variable also depending on the anatomical sites
in which their activation occurs. Accordingly, both factors
involved in bone resorption and factor promoting new bone
formation have been described at the subchondral bone
marrow level [51, 73], and definitive conclusions on the
functional significance of marrow follicles cannot be drawn
from current knowledge.
4.4. LymphNodes. Secondary lymphoid organs are a primary
site for the generation of adaptive responses and for the
regulation of inflammatory reactions in peripheral drained
tissues. Understanding the biological processes related to B
cells in secondary lymphoid organs in course of autoimmu-
nity is therefore a central issue with considerable scientific
and clinical perspectives. The scarce accessibility of these
compartments in humans through invasive procedures has
however limited our comprehension of their behavior during
RA, with most of the available data derived from studies on
experimental animal models.
In this context, lymph node involvement appears as an
early event and has been recognized as a fundamental com-
ponent of the arthritis process. An increase in the percentage
of B lymphocytes as well as a high proliferation of CD8+ cells
was observed in regional lymphnodes in the latency period of
adjuvant arthritis [77]. In the K/B ×Nmodel of spontaneous
autoimmunity, the lymph nodes draining the distal joints
were found essential for the amplification of the arthritogenic
B-cell response [78]. Similarly, structural changes in lymph
nodes have been reported in TNF-transgenic mice [79, 80],
with evidence indicating a role of local B cells in different
aspects of the disease. Lymph nodes draining inflamed joints
are indeed selectively characterized by local differentiation
of CD23+CD21highCD1dhigh B cells (a population defined
“Bin”, B cells in inflamed nodes) [81, 82]. Such cell population
has been shown to display an enhanced ability to capture and
process antigen-immune complexes, to express greater levels
of MHC class II and costimulatory antigens and to exhibit
a GC phenotype at higher rate compared with follicular
B cells [82]. These data suggest that draining lymph nodes
can accumulate B cell subsets with enhanced immuno-
logical potential, which may contribute to autoimmunity
progression in predisposed individuals. Of considerable rel-
evance, B cells and Bin localized in draining lymph nodes
from TNF-transgenic mice have been shown to play a role in
arthritis progression also through nonimmunological mech-
anisms. B cells accumulating in reactive lymph nodes can
indeed translocate from the follicular area to the sinusoidal
lymphatic sinuses, impairing afferent lymphatic drainage and
leading to lymph node collapse, a process associated with
increased inflammation and erosive changes in the drained
joint [83]. These events have been shown to be reversible
by B-cell depleting agents, explaining a potential alternative
mechanism of action of B cell-targeted therapies in RA
[84].
Although the specific relevance of these findings to
human disease is currently unknown, there is growing
evidence indicating that draining lymph nodes can be inte-
grating part of RA pathologic processes. Former histologic
studies on lymph node biopsies from different anatomic
sites in established RA described follicular hyperplasia and
interfollicular plasmacytosis [85] as well as increased GCs
with high B-cell activity [86]. More recent data exploiting
power Doppler ultrasound demonstrated the possibility to
capture significant structural and vascular flow changes in
axillary lymph node of patients with active disease, including
hypertrophy of cortical regions [87]. Supporting these data,
flow cytometry analysis of inguinal lymph node cells isolated
from ultrasound-guided biopsies in in early arthritis patients
showed an increase in activated CD69+ CD8+ cells and
CD19+ B cells compared to healthy controls, suggesting an
increased immune cell activation within the lymph node
compartment [88]. Ultrasound-guided biopsy of inguinal
lymph nodes appears feasible and safe [89] and promises to
yield important information in the next future.
5. B Cells as Biomarkers
The discovery of the pathophysiological role for B cells in
regulating several aspects of the immune response in RA
has greatly refined our understanding of the disease over
the last decade. Despite common considerations reviewed
so far, RA remains a heterogeneous syndrome in terms
of clinical expression and long-term course, and different
pathogenic pathways are likely to be differently activated in
different patients or at least in different phases of the disease.
In particular, the relative contribution of B lymphocytes
appears greatly variable, as inferred at least by the existence
of a seropositive and a seronegative subtype of RA. As a
consequence, the B-cell signature is also being extensively
investigated in its possible clinical applications, in search of
new biomarkers able to complement and expand the well-
established diagnostic and prognostic value of RA-related
autoantibodies. The reader is referred to comprehensive
reviews on the clinical significance of ACPA and RF in
RA [90, 91]. Here, we will summarize recent data on non-
antibody B-cell biomarkers.
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5.1. Disease Diagnosis
5.1.1. Serum B-Cell Markers and B Cell-Related Factors. The
performance of markers of B-cell activation in the classifi-
cation of early inflammatory arthritides has been extensively
investigated in the ESPOIR cohort, a large Frenchmulticenter
prospective cohort including patients with early arthritis of
<6 months duration [92, 93]. In this cohort, serum markers
of B-cell activation, such as levels of IgG, IgA, free light chains
(FLC) of Ig and 𝛽2-microglobulin, have been reported to be
increased in early RA compared to undifferentiated arthritis
(UA) [92]. Furthermore, some of these markers, such as 𝛽2-
microglobulin, maintained an independent predictive ability
for RA diagnosis in multivariable regression models also
including ACPA and acute phase reactants [92]. Importantly,
neither the increase in BAFF serum levels nor BAFF gene
polymorphism could discriminate early RA from UA [92].
However, caution should be put in interpreting the clinical
associations of BAFF serum levels in RA and autoimmune
diseases in general. In fact, BAFF family members exist
in several different forms depending on protein structure,
splice variants, glycosylation, and cleavage, eachwith possible
specific biological activities [94], and BAFF quantification
based on ELISA commercial kits was found to be largely
inaccurate [95].
Further studies into the ESPOIR cohort have confirmed
that, among a broad panel of cytokines investigated, IL-6
and IL-21 only were associated with increased proportions
of autoantibodies and higher levels of markers of B-cell acti-
vation [93]. Again, baseline levels of IL-6 could discriminate
RA from UA with a positive predictive value of 85.8% and
a negative predictive value of 32.8% [93]. In multivariate
analysis, the association of IL-6 with RA diagnosis was inde-
pendent of ACPA positivity and markers of inflammation,
with an OR of 1.9. Higher levels in RA compared to UA were
also found for IL-21. It should be noted that a proportion
of patients classified as suffering from UA at baseline also
displayed high levels of markers of B-cell activation [92]. In
this context, novel biomarkers reflecting RA pathogenesis
could be tested for their performance in improving the
recognition and management of chronic arthritides since the
very early phases of the disease, before the fulfillment of any
established classification criterion [96].
5.1.2. Synovial Tissue B Cells and B Cell-Related Factors.
In 1978, Goldenberg and Cohen [97], after histopathologic
evaluation of synovial tissues obtained from 90 patients
suffering from different rheumatic diseases, concluded that
the presence of lymphoid follicles could be regarded as a
specific feature of RA. Over the years, several investigators
have revised this assumption demonstrating that most of the
chronic inflammatory arthritides share common histopatho-
logic features, including the local organization of infiltrating
mononuclear cells into aggregational structures [98–100].
A recent prospective study involving 93 patients with early
arthritis of<12months duration has failed to demonstrate any
diagnostic value of synovial lymphocyte aggregates evaluated
by means of T-cell markers [100]. Although the wide hetero-
geneity in synovial tissue patterns observed among patients
with RA and the high degree of overlapping among different
disease entities make the use of synovial tissue analysis at
present unrealistic for diagnostic purposes, caution should
be put in interpreting the current controversies in literature.
No standard consensus indeed exists on the classification
of synovitides in either diffuse or aggregational, as the two
patterns of infiltration actually represent a continuum of
overlapping forms of variable intensity rather than mutually
exclusive histotypes [60]. Accordingly, preliminary data in 84
sequentially recruited patients with at least 1 swollen joint
and disease duration<12months indicate that the presence of
synovial aggregates does associate with baseline RA diagnosis
according to the 1987 criteria [101], thus reopening the
dispute on the clinical significance of lymphocyte infiltration
patterns. An additional layer of complexity resides on the
histological criteria adopted to identify lymphocytic aggre-
gates (B cells only/T cells only/B + T cells). When specifically
looking at B cells as core elements of lymphoid clusters, the
numbers of CD38+ plasma cells andCD22+B cells (but not of
CD3+T cell aggregates) were the best discriminatingmarkers
comparing RA to non-RA in 95 patients with active UA at
time of presentation [102].
5.2. Disease Phenotype and Prognosis
5.2.1. SerumB-CellMarkers and BCell-Related Factors. Over-
all, markers of B-cell activation in early RA appear mostly
associated with autoantibodies as well as with inflammatory
features [92]. The interpretation of their possible prognostic
value thus requires caution and should take into account
confounding factors. Yet, in the ESPOIR cohort, some B-
cell markers, such as total IgA and kappa FLCs, turned out
to be independently associated with radiographic erosions
at disease onset [92], and IL-6 and IL-21 serum levels were
also predictive of rapid radiographic progression at 1 year
irrespective of clinical inflammation [93].
Studies analyzing the prognostic value of the B-cell
chemoattractant CXCL13 are opening promising perspec-
tives in the field of biomarker discovery in RA. CXCL13
is critically involved in several autoimmune diseases by
redistributing B lymphocytes into injured tissues, organizing
their microanatomical positioning and possibly enhancing
their BCR-mediated activation [103]. Serum levels of CXCL13
are increased in early RA patients compared to healthy
controls [104, 105], and synovial CXCL13 has been shown to
correlate with accumulation of CXCL13 protein in the serum
[106, 107]. CXCL13 appears as a marker of severity in RA.
A large prospective study has indeed shown that early RA
patients with the highest levels of serum CXCL13 are those
with the highest rate of progression of joint damage over long-
term follow-up [104]. In line with these data, in 161 untreated
RA patients with disease duration <12 months, baseline
CXCL13 levels >100 pg/mL predicted persistent subclinical
ultrasonographic synovitis despite effective treatment with
conventional DMARDs [105]. Although CXCL13 levels at
baseline correlated with the ACPA status as well as with dis-
ease activity, the predictive value of the chemokine appeared
independent of both factors [104, 105]. Important issues that
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need to be clarified for serum CXCL13 to be established as
an additional biomarker include demonstration of whether
circulating levels of the chemokine reliably reflect synovial
synthesis and different synovial pathotypes and howwell they
outperform currently available tests in the clinical assessment
and prognostic stratification of RA.
5.2.2. Synovial Tissue B Cells and B Cell-Related Factors.
Because RA synovia harvested from different RA patients
show wide variations in the size and density distribution of
B-cell aggregates, a questionwhich therefore arises is whether
such heterogeneity translates into specific phenotypic differ-
ences and variable disease outcomes.
In animal models, inflammatory stimuli promote the
local migration and retention of B lymphocytes within non-
lymphoid tissues through the induction of chemoattracting
factors, such as CXCL13, but they are no further required
for their maintenance [108, 109]. Accordingly, synovial levels
of CXCL13 expression and lymphocyte infiltration appear
associated with features of local disease activity in early RA
[100, 107], whilst the correlation is weaker or even lost for
longer duration [106, 107, 110]. Thus, “B-cell synovitis” does
not per se appear synonymous to clinically active disease.
Despite the lack of overt inflammatory features, continuous
synovial expression of CXCL13 may mark ongoing immune
cell activation and the establishment of a local milieu favour-
ing tissue remodeling, as suggested by increased levels ofAID,
IFN-𝛾, and IL-2 expression and a higher RANKL/OPG ratio
in tissues expressing increasing levels of the chemokine [107].
Accordingly, patients displaying the highest levels of CXCL13
appear to suffer frommore severe RA in cross-sectional eval-
uations [107]. Similarly, the density of CD79a-positive B cells
has been shown to positively correlate with radiographic joint
damage, which was instead unrelated to other inflammatory
features such as T cells, lining or sublining macrophages, and
capillary angiogenesis [111]. Whether such cross-sectional
association also has prognostic significance over long-term
follow-up has however remained difficult to establish, and
large prospective studies on early RA are currently not
available. Yet, in a small cohort of 18 patients with short
disease duration, the degree of synovial CD20 expression at
the metacarpophalangeal joints was shown to significantly
correlate with radiological damage at 3 years independent
of other features of local inflammation [112]. Overall, the
few available studies seem to suggest that local B cell-
centred processesmight somehow be associated with features
of disease severity. Importantly, these could be eventually
captured prospectively if the B-cell pathotype of synovial
inflammation is analyzed in its quantitative and functional
features. Given the strong relationship between synovitis
and bone damage, the exploration of possible biomarkers of
disease severity in this area could be conceivably fruitful [113].
5.3. Response to Therapy
5.3.1. Peripheral Blood B Cells, B-Cell Markers, and B Cell-
Related Factors. Given the availability of therapies directly
targeting B cells, research on the possible role of B-cell
disturbances in predicting response to treatment has natu-
rally focused on rituximab.
Rituximab induces nearly complete depletion of CD20+
B lymphocytes in the peripheral blood which is sustained
for several months after treatment [114]. Reconstitution of
peripheral blood B cells first involves immature B cells,
followed by naive B cells. In contrast, memory B cells show a
slow and delayed repopulation [115–117]. Interestingly, better
response to rituximab and late relapse in responders have
been associated with decrease in memory B cells [56, 116,
117], confirming the pathogenic involvement of this cell
population in RA. Furthermore, a higher number of pre-
plasma cells before treatment have been associated with
incomplete B-cell depletion and a worse clinical response
[118], and elegant studies analyzing quantitativemRNAassays
for B lineage cells have confirmed that markers for antibody-
secreting plasmablasts predict nonresponse to anti-CD20
therapy [119].
Because extensive phenotyping of B-cell subpopulations
is costly and not easily accessible in routine care, predictors
of response have been also searched within standard markers
of B-cell activation, such as serum Igs, FLC, and BAFF. In
the SMART study, involving 208 patients with active RA in
whom anti-TNF agents had failed or were contraindicated,
serum IgG > 12.66 gm/liter (upper limit of normal) arose
as independent predictors of response to rituximab with
an OR of 2.11 and synergistic with RF and/or ACPA [120],
confirming that anti-CD20 treatments may be particularly
indicated in the B cell-driven subtype of RA. Although BAFF
levels were not found to be associatedwith clinical response, a
recent study analyzing 138 seropositive RA patients indicates
BAFF levels >1011 pg/ml as an independent predictor of a
good EULAR response in this subgroup of patients [121].
Again, contrasting results might depend on the different
clinical features of the patients’ population being analyzed,
as well as on the inaccuracy of BAFF serum level mea-
surements due to the biological complexity of this cytokine
[94, 95].
Since trafficking and repopulation patterns of B cells
following rituximab are relevant to the mechanism of action
of rituximab itself, recent studies have focused on the role of
B cell attracting chemokines as potentialmarkers of response.
In a small open label study of rituximab involving 20 patients
with active RA (ARISE trial), high baseline serum levels of
CXCL13 were predictive of B-cell repopulation at 6 months
after treatment [106]. Although in the larger SMART study
CXCL13 was not associated with EULAR response at week
24, another chemokine involved in B-cell migration, that is,
CCL19, turned out to be predictive in a multivariable model
not including autoantibodies [59].
5.3.2. Synovial Tissue B Cells and B Cell-Related Factors.
Whilst variations in the degree of sublining macrophage
infiltration can early and reliably track the clinical efficacy of
conventional and experimental treatments in RA [122], the
effects of therapies on synovial B cells/B-cell markers and
the ability of B-cell infiltration to predict different clinical
responses are less clear.
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Although not directly addressed, conventional DMARDs
do not seem to significantly affect synovial B-cell pathways.
A recent study comparing the effects of tocilizumab with
methotrexate failed to report significant changes in B cell and
plasma cell numbers in 15 patients with early RA receiving
standard dosages ofMTX for 6months [123]. Relevantly, gene
expression levels of CXCL13 also remained unchanged [123],
confirming that this chemokine may be a marker of more
refractory synovitides with worst disease evolution upon
conventional treatments [104–107]. In contrast to synthetic
DMARDs, biological drugs may interfere with local B-cell
pathology. Reductions in B-cell numbers or loss of follicular
architecture have been reported in association with effective
treatment with either TNF-inhibitors, tocilizumab, or abata-
cept [110, 123–125]. Also, the presence of well-organized B-T
cell follicles has been proposed as an independent predictor
of lower response to anti-TNF agents [110].
Synovial tissue analysis following rituximab treatment
has provided suggestive results demonstrating that, com-
pared to the almost complete depletion of CD20+ B lym-
phocytes in the peripheral blood, depletion in the synovium
is less complete and varies between patients irrespective of
the clinical response [126–129]. In 24 RA patients undergo-
ing serial synovial biopsies, B-cell levels at baseline were
not predictors of response. Clinical response was instead
predicted by the reduction of plasma cells, presumably as a
consequence of depletion of their memory B cell precursors
[127]. Accordingly, a low disease activity state following
rituximabwas associatedwith reduced infiltration ofCD79a+
CD20− plasma cells in the synovium [129]. Collectively,
these findings support the notion that therapies aimed at
interfering with B-cell pathology in RA could be improved
through the targeting of additional players, such as CD20-
negative plasma cells, as well as additional compartments,
such as the synovial tissue.
6. Conclusions
The contribution of B lymphocytes to RA pathogenesis
goes well beyond autoantibody production and extends to
areas unsuspected until recent years. Knowledge will expand
further with the entry of new B cell-targeted therapies into
the market. The redistribution of B-cell subsets in different
anatomic compartments during the course of the disease
should be taken into account to dissect the intricate mecha-
nisms of autoreactive B-cell activation and survival. Finally,
and perhaps more relevantly, a broader insight into B-cell
pathologic reactions could help generating novel biomarkers
of disease diagnosis, prognosis, and response to therapy in
patients with RA.
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